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tional. However, classified as G1 or G2, Si-NENs are often 
discovered at an advanced disease stage – regional disease 
(36%) and distant metastasis (48%) are present – and per-
cutaneous biopsy of a liver lesion is often the diagnostic 
procedure performed  [2, 7] . 
 Previous ENETS guidelines  [1, 8, 9] have discussed ex-
tensively the clinical symptomology, diagnosis and treat-
ment of localized, regionalized as well as distant Si-NENs. 
This fourth edition of the ENETS guidelines is an update 
of the third version for the management of patients with 
Si-NENs published in 2012  [1] in order to further stan-
dardize and improve the early diagnosis and treatment
of Si-NEN patients. This guideline deals with non-meta-
 Introduction  
 Neuroendocrine neoplasms (NENs) of the small intes-
tine (i.e. the ileum and jejunum; Si-NENs)  [1] comprise 
at least the third largest subgroups of NENs within the 
gastroenteropancreatic system  [2] . Because of a better 
knowledge of the molecular and cell-biological aspects as 
well as the clear pathohistological characterization of this 
tumor entity  [3] , a worldwide overall increase of NENs is 
reported  [4] ; the location in the small intestine reaches in 
some publications the largest absolute number  [5, 6] .
 Si-NENs derive from serotonin-producing entero-
chromaffin cells. The biology of these tumors is different 
from other NENs of the digestive tract, characterized by 
a low proliferation rate [the vast majority are grade 1 (G1) 
and G2], they are often indolent; G3 tumors are excep-
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static NENs originating from the small bowel, originally 
described as ‘carcinoid’ tumors by Oberndorfer in 1907 
 [10] .
 This update does not include metastatic disease which 
is covered in a separate paper of this issue; this other pa-
per also discusses guidelines for medical and other treat-
ment options of the ‘carcinoid syndrome’, since this oc-
curs almost exclusively when the tumor is metastatic. The 
carcinoid heart disease (CHD or Hedinger syndrome), 
however, is covered in this paper, since early recognition 
and treatment is important for this complication of the 
carcinoid syndrome.
 Epidemiology and Prognosis 
 Si-NENs are an overall relatively rare entity with a re-
ported incidence between 0.32/100,000 in England  [11] , 
0.33/100,000 in Japan  [12] , 0.67/100,000 in the USA  [6] , 
0.81/100,000 in Norway  [13] and 1.12/100,000 in Sweden 
 [14] according to the most recent literature. Malignant 
Si-NENs have been reported with an incidence of 
0.29/100,000  [2] ; in this study, malignant Si-NENs made 
up approximately half of all NENs, while other studies 
have shown lower numbers, i.e. 20–35%  [1, 6, 13] . The 
mean age at initial diagnosis is in the late 50s in several 
cohorts, with the majority of cases occurring in the 7th 
decade  [12, 15–17] . The incidence of Si-NENs has not 
shown a gender preference in some series  [11, 15, 17] with 
a slight male preponderance in others  [12, 16, 18] . While 
the incidence of Si-NENs may be lower in persons of 
Asian descent  [6, 12] , it seems to be higher in African 
Americans in the SEER data-base  [6] . Si-NENs constitute 
up to one third or even half of all small bowel neoplasms 
 [2, 16] . The ‘true’ incidence of Si-NENs in post-mortem 
studies is much higher (1.22/100) and suggests that these 
NENs may be much more abundant at early or very early 
stages but do not manifest themselves clinically and are 
not diagnosed during life  [19] . 
 The prognosis of Si-NENs depends on both staging 
and grading, which is reflected in the WHO classification 
of 2010  [20] . This has also been shown in a recent study 
in which the Ki-67 grading system as well as TNM staging 
for Si-NENs have been validated; Jann et al.  [21] reported 
5-year tumor-specific survival rates for jejuno-ileal NENs 
from an oncological cohort of 100% for stage I and II, 
97.1% for stage III and 84.8% for stage IV Si-NENs. Grad-
ing-dependent 5-year tumor-specific survival rates are 
93.8% for G1, 83.0% for G2 and 50.0% for the very rare 
G3 Si-NENs  [21] . The SEER analysis for Si-NENs per-
formed by Boudreaux et al. revealed 5-year overall sur-
vival rates of approximately 72% for locoregional spread 
and approximately 55% for NENs with distant metastases 
 [22] . In the Spanish NET registry, 5-year survival for the 
whole cohort of ‘enteric carcinoid tumors’ was 77.6% 
 [15] , and this figure was only 61% in the Netherlands 
Cancer Registry (NCR) reported approximately 10 years 
earlier  [23] . The SEER data do not suggest a significant 
survival difference between different ethnicities  [6] . The 
prognosis for Si-NENs is, thus, considerably better than 
for other small intestinal neoplasms such as lymphomas, 
adenocarcinomas and sarcomas  [16] . In the older patient 
group of more than 60 years at initial diagnosis, the out-
come figures may be worse as was suggested by an analy-
sis of the population-based Florida Cancer Data System 
(FCDS)  [24] , but this may not be exclusively related to 
NENs but rather other secondary neoplasms or other age-
related causes of death  [18] .
 Although recent data  [25] suggest better overall or tu-
mor-specific outcome figures, the data sets are not com-
pletely comparable as they are analyzed at different tumor 
stages. However, as has been suggested by Yao et al.  [6] , 
the overall outcome has probably improved over the last 
25 years which may be related to better diagnosis, effec-
tive treatment options and multimodal sequential or si-
multaneous treatments. This aspect, however, has not 
been specifically shown by every study  [18] , and will also 
undoubtedly be very hard to prove.
 Localized mesenteric lymph node metastases, distant 
abdominal lymph node metastases, liver tumor burden 
and extra-abdominal metastases seem independent prog-
nostic factors by multivariate analysis  [26] .
 Minimal Consensus Statement on Epidemiology and 
Prognosis 
 The former terminology of midgut and hindgut origin is in-
accurate and hence these tumors are classified as jejuno-ileal,
appendiceal, cecal, colonic or rectal NENs. The clinical incidence 
of Si-NENs is considerably lower than the incidence at autopsy 
(approx. 1: 100). It is probably higher than stated earlier in the lit-
erature. Figures from the SEER and other registries indicate a
significant rise of the reported annual incidence of 0.67–
0.81/100,000/year for Si-NENs. The incidence rate may be con-
siderably lower in Asia with 0.20/100,000/year as suggested by 
Japanese data. Si-NENs represent 30–50% of all small bowel neo-
plasms. The incidence rates have increased in more recent years. 
The average age at diagnosis for patients with these tumors is be-
tween 60 and 65 years. According to the literature, there is a slight 
male preponderance, and there are some ethnic differences. Afri-
can Americans have a higher incidence rate than Caucasians. 
 Ki-67 grading is an important prognostic stratifier and is 
therefore mandatory in pathological reporting. Survival rates 
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strongly depend on histopathological WHO classification and 
TNM stage: 5-year overall survival rates for all stages reach be-
tween 50 and 60%. In Si-NEN patients with locally advanced dis-
ease, 5-year survival reaches 80–100%, and in patients with re-
gional lymph node involvement it reaches 70–80% (stages I–
IIIa). Survival in stage IV disease patients lies between 35 and 
80%. Series presenting analyses from more recent data collec-
tions observe even more favorable outcome. 
 Clinical Presentation 
 Nonspecific symptoms (vague abdominal pain or 
weight loss) were evident in 37% of all Si-NEN patients. 
Retrospectively, specific clinical symptoms either local 
(e.g. local stenosis or melena) or systemic (e.g. diarrhea 
or flushing) were reported in 21.5%, respectively  [7] . Lan-
derholm et al.  [14] reported that even Si-NENs with dis-
tant metastasis may present without symptoms and the 
‘carcinoid syndrome’ is infrequently seen. Therefore, it is 
recommended that primary-care physicians should keep 
in mind NENs and their vague nonspecific clinical fea-
tures and start appropriate diagnostic testing early  [27] .
 Si-NENs are frequently detected only when searching 
for a primary tumor in either asymptomatic or symptom-
atic patients (e.g., with carcinoid syndrome) with metas-
tases; they can rarely be found incidentally, for example 
on screening colonoscopy in the terminal ileum or on a 
CT scan performed in another clinical context. The most 
frequent clinical symptom from single- or multi-centric 
series as well as from population-based data sources is 
nonspecific abdominal pain  [7, 14, 28–31] which may be 
due to various reasons: dysmotility of the small bowel 
wall, small bowel obstruction, intermittent mesenteric 
ischemia caused by mesenteric root fibrosis, but also 
functional causes such as secretory diarrhea and bacterial 
overgrowth. Other nonspecific symptoms such as weight 
loss, fatigue and (rarely) fever of unknown origin may 
also occur. Tumor-mass-related symptoms due to bowel 
obstruction with nausea and vomiting, jaundice in case of 
metastatic cholestasis and even GI bleeding may also oc-
cur, but in a smaller proportion of patients  [7, 14, 28–31] . 
The desmoplastic reaction leading to visceral fibrosis may 
culminate in small bowel ischemia or hydronephrosis 
from some degree of retroperitoneal fibrosis, although 
these are rare problems.
 Tumor-specific hormone-hypersecretion-related 
symptoms from the carcinoid syndrome comprise secre-
tory diarrhea (60–80%), flushing (60–85%) and intermit-
tent bronchial wheezing (which is frequently not clini-
cally apparent; <10%) and most importantly right heart 
valve fibrosis with CHD (Hedinger syndrome; in up to 
20%)  [18, 29–31] . These manifestations are always associ-
ated with metastatic disease and by far most often with 
liver metastasis, which allows bypassing of hepatic clear-
ance of serotonin from the portal circulation  [28, 31, 32] . 
There is no evidence that the carcinoid syndrome per se, 
independent of metastatic disease, has an influence on 
prognosis  [21] except for clinically manifest right-sided 
heart failure of CHD (see below).
 A ‘carcinoid crisis’ is a severe and potentially fatal ex-
acerbation stemming from hormone or peptide hyperse-
cretion, leading to symptoms and signs often provoked 
by anesthesia or invasive procedures such as surgery  [33] . 
The clinical picture includes flushing, hypo- or hyper-
tension, diarrhea, severe bronchospasm and cardiac
arrhythmias.
 Minimal Consensus Statement on Clinical 
Presentation 
 Abdominal pain is the most frequent initial symptom in pa-
tients presenting with Si-NENs from the small bowel (often as-
similating irritable bowel syndrome). The carcinoid syndrome is 
seen in approximately 20–30% of patients with metastases, this 
percentage is higher than previously stated. Small bowel ischemia 
can be another cause of diarrhea and pain besides hormone-hy-
persecretion-related diarrhea. Flushing and diarrhea are thought 
to be the cardinal symptoms in functional tumors and are equal-
ly (80%) present. It is emphasized that the carcinoid syndrome is 
usually seen in patients with liver metastases (in 95% of all pa-
tients), but excess tachykinin or serotonin production from ret-
roperitoneal metastases or ovarian tumors/metastases can by-
pass the liver, enter the systemic circulation and cause the typical 
carcinoid syndrome (in up to 5% of the patients).
 Imaging 
 Cross-sectional imaging by either CT following mod-
ern protocols (3-phase contrast-enhanced multi-slice 
CT) or MRI (also with the use of contrast media) is the 
cornerstone of indirect imaging of the abdomen for ini-
tial staging as well as preoperative diagnosis  [34, 35] . By 
this approach, the primary tumor may sometimes be im-
aged, but lymph node and/or distant metastases can reg-
ularly be either detected or ruled out, respectively. In the 
case of an unknown primary tumor, thoracic scanning 
(preferably with CT) may also be necessary to either de-
tect or rule out a bronchial primary NEN. CT or MR en-
teroclysis may provide additional benefit for primary
tumor detection in the small intestine with very good 
sensitivities and specificities in institutions where either 
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of them is available  [36, 37] . Transabdominal ultraso-
nography may be used for screening of hepatic metasta-
ses with good results  [38] , but the technique is investiga-
tor dependent; in individual cases, transabdominal ultra-
sonography of the small bowel with high-frequency 
probes (10 or 12 MHz) may also detect a small intestinal 
primary tumor and/or mesenteric lymph node metasta-
ses. However, for long-term follow-up purposes and reli-
able comparability, CT or MRI provides a better investi-
gator-independent basis.
 Direct visualization may be possible with regular colo-
noscopy if the tumor is prolapsed through the ileocecal 
valve into the colon, or if intubation of the ileum is per-
formed during the investigation. For investigations of 
more proximal parts of the ileum or of the jejunum, the 
newer modalities of enteroscopy including video-capsule 
endoscopy (VCE)  [39] or double-balloon enteroscopy  [40] 
may be effective, although their role in routine staging still 
has to be established, and they are not widely available. The 
use of VCE as part of the diagnostic work-up in selected 
patients presenting with metastatic NENs of unknown
primary is suggested. However, the clinical utility of this 
technology requires clearer definition  [41] . There are no 
data on potential procedural risks of these methods in 
NEN which should always be weighed against the benefits 
of tumor localization and/or even histological confirma-
tion by luminal biopsy. At least, in the case of impending 
small bowel occlusion, VCE is absolutely contraindicated.
 Somatostatin receptor imaging (SRI) of Si-NENs de-
pends on the presence of somatostatin receptors in NEN, 
particularly of subtype 2 (SSR-2), which is the receptor to 
which the currently used ligands for these modalities bind 
with the highest affinity. Linked to the ligand are either 
radionuclides that can be detected by somatostatin re-
ceptor scintigraphy (SRS; e.g.  111 Indium) or by positron 
emission tomography (PET; e.g.  68 Gallium) scanning 
 [42–54] . For Si-NEN PET scanning, the use of  18 fluoro-
deoxyglucose cannot be recommended, since it has a low 
sensitivity for well-differentiated low-grade NEN, which 
comprise by far the majority of Si-NENs. However, it is 
recommended in G3 NENs independent of the location 
of the tumor. Other newer traces such as  11 carbon-5-hy-
droxytryptophane or  18 fluoro-dihydroxyphenylalanine 
(DOPA) have shown promising results but are even less 
available and await further study  [49, 55] . SRI has sen-
sitivities of approximately 90% for primary/nodal Si-
NENs and of >95% for liver metastases and is, therefore, 
an important tool for initial staging as well as for follow-
up.  68 Ga PET, preferably with simultaneous contrast CT 
(functional imaging), see  figure 1 , may be even more sen-
sitive and change management in an additional 20–30% 
of the cases. Particularly for the detection of small tumors 
within the jejuno-ileum, as well as for the preoperative 
exclusion of distant metastases not detected by other di-
rect or indirect imaging modalities, PET scanning may be 
useful, but this requires further prospective studies.
 68 Ga-DOTATOC PET/CT was found to be more use-
ful to  111 In-DTPA octreotide SPECT/CT when searching 
for a primary NEN in patients with unknown or suspect-
ed disease  [56] .
 SRI may also be useful in detecting silent or clinically 
suspected bone metastases, which represent the fourth 
most frequent metastatic localization (after lymph nodes, 
liver and the lungs in descending frequency)  [17, 30] ; al-
though conventional bone scintigraphy using 99m-tech-
netium-DPD scintigraphy may also be useful  [57] .
 A rational step-wise approach of diagnostic modali-
ties, as suggested in  figure 1 , is recommended to make the 
optimal use of the available methods and limited resourc-
es, with the least invasive methodology for the patient and 
the most effective outcome for patient management.
 Minimal Consensus Statement on Imaging 
 In the search for a primary tumor, cross-sectional imaging 
with CT and/or MRI should be followed by  68 Ga-DOTATOC 
PET in combination with native or preferably 3-phase contrast-
enhanced CT (functional imaging) or if not available SRS SPECT/
CT. In general, fusion imaging with CT is always preferable. 
Newer PET imaging techniques may be useful but require a cy-
clotron and are unlikely to become generally available.  18 Fluoro-
deoxyglucose PET is not usually useful in these lower-grade tu-
mors. If localizing a primary tumor is required in surgical candi-
dates prior to bowel resection, either CT-/MR-water enteroclysis 
or endoscopic techniques such as VCE or double-balloon enter-
oscopy may be used according to local expertise, but potential 
risks need to be weighed against benefits such as precise preop-
erative localization particularly of multi-centric NENs. Colonos-
copy should be performed because it may detect primary tumors 
in the distal ileum and is necessary to rule out synchronous neo-
plastic disease (particularly colorectal cancer). For cardiac diag-
nostics to investigate for CHD, please see the section below.
 Laboratory Tests 
 Serum chromogranin A (CgA) remains a relatively 
sensitive marker for NENs of all origins including Si-
NENs  [58–60] . CgA has also more recently been shown 
to prognostically predict significantly differing groups, 
with higher levels of CgA indicating a worse prognosis, 
probably related to increased tumor cell mass  [61, 62] . 
For longitudinal follow-up purposes, it is important to 
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note that absolute CgA values may differ significantly be-
tween different assays  [63] , and therefore it is recom-
mended to perform repeated measurements in the same 
laboratory or at least with the same assay whenever pos-
sible. Furthermore, the differential diagnosis of elevated 
CgA values such as in patients on proton pump inhibi-
tors (PPIs), with chronic atrophic gastritis, chronic renal 
failure, liver cirrhosis or congestive heart failure, as well 
as other CgA-secreting neoplasms (e.g. hepatocellular 
carcinoma, medullary thyroid carcinoma) needs to be 
considered when CgA values are interpreted  [64–66] . 
CgA may signal NEN recurrence after successful curative 
resection early in patients with a small tumor burden  [59, 
67] .
 Endocrine tumors of the jejuno-ileum produce sero-
tonin and elevated 24-hour urinary 5-hydroxy indole 
acetic acid (5-HIAA) levels as a product of the metabo-
lism of serotonin  [68, 69] . 5-HIAA has a sensitivity of up 
to 100% and a specificity of 85–90% for detecting a car-
cinoid syndrome, and a sensitivity of 70–75% and a 
specificity of close to 100% for predicting a primary tu-
mor in the jejuno-ileum  [58, 60] . Urinary 5-HIAA 
should be collected with strict dietary restrictions to 
avoid false positive levels  [70] . Serum serotonin deter-
minations are less sensitive and specific and are, there-
fore, not recommended; serotonin measurements in 
platelets, where serotonin is stored depending on its 
availability in the systemic circulation, may be even 
more sensitive, but is not widely available and therefore 
currently impractical  [69] .
 Minimal Consensus Statement on Laboratory Tests 
 The minimally required biochemical tests include plasma 
CgA and urinary 5-HIAA. These tests should be performed at the 
first visit and then for follow-up or on suspicion of NEN recur-
rence or progression. Newer markers, either biochemical or 
based on circulating NEN cells, require further validation. Neu-
ron-specific enolase has no role for the diagnosis of these almost 
always well- to moderately differentiated NEN (G1/2 NET). 
Clinical diagnosis: incidental or ?????????? 
Abdominal surgery 
(incl. emergency) 
Abdominal 
sonography Endoscopy 
Primary tumor and/or Ln mts Liver lesions - biopsy (Jejuno-) ileal primary tumor 
Histopathological diagnosis 
?  Hematoxylin-eosin staining 
?  Immunohistochemical staining: chromogranin A (CgA), synaptophysin – posi?ve for siNEN: serotonin; cdx-2 
?  Grading: Ki67 index; mito?c index 
Clinical staging ??????????? 
Imaging  
Cross-???????? (CT, MRI) or ????????? imaging 
(G1 andG2: SSR- PET-CT; G3: FDG-PET-CT 
Biochemistry 
CgA 
5-HIAA 
Primary tumors with/without mets No primary 
Normal 
Elevated 
Primary 
only Ln-mets 
Distant mets 
(distant Lns, 
liver, bone, 
lung) 
 
?  Capsule 
endoscopy 
?  Double-balloon 
enteroscopy 
?  Colonoscopy* 
  
Asymptoma?? ?????????? 
Non-?????????? ?????????? 
Echocardiography 
NT-pro-BNP  
(to exclude or ???????? 
Carcinoid heart disease 
(Hedinger’s Syndrom) 
 Fig. 1. Diagnostic algorithm of Si-NENs. Mets = Metastasis; Ln = 
lymph nodes; NT-pro-BNP = B-type natriuretic peptide; 5-
HIAA – 5-hydroxyindoleacetic acid is a biochemically determin-
able metabolite of serotonin, a specific mediator of the carcinoid 
syndrome; CgA – chromogranin A is non-specific for the carci-
noid syndrome; SSR = somatostatin receptor; PET = positron 
emission tomography; CT = X-ray computed tomography;
FDG = fluorodeoxyglucose (18F).  * If not performed previously: 
colonoscopy including the terminal ileum and to exclude a sec-
ondary primary. 
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 Pathology  
 A pathological diagnosis is mandatory in all cases and 
usually obtained on ultrasonography-guided liver biopsy 
or surgical biopsy. A pathological diagnosis of jejunal-il-
eal tumors is achieved using hematoxylin-eosin staining 
and immunohistochemical staining with CgA and synap-
tophysin  [3, 20, 71, 72] . As opposed to serum levels of 
CgA, weaker CgA staining on immunohistochemistry 
may indicate a poorer prognosis  [30, 73] . A determina-
tion of the mitotic index and a calculation of the Ki-67 
index by immunohistochemistry are mandatory and 
prognostically relevant in jejuno-ileal NENs  [3, 21] . The 
tumors should be classified according to the WHO sys-
tem  [20] including TNM staging  [3, 72] and Ki-67 grad-
ing  [3, 20, 72] ( table 1 ). Immunohistochemical staining 
for somatostatin receptors 2 (SSR-2) has been suggested 
by several studies  [74] to correlate with, or at least be in-
dicative of, a therapeutic response to somatostatin ana-
logue (SSA) treatment. However, currently it can only be 
considered optional, since methodological variations and 
current data do not show a completely conclusive pattern. 
Thus, SSA treatment may be initiated although SSR-2 
staining may be weak or even absent on immunohisto-
chemistry.
 In patients with liver metastases from a NEN of un-
known primary tumor localization, nuclear immunohis-
tochemical positivity for cdx-2 and/or serotonin with 
negativity for TTF-1 and ISL-1 is supportive of intestinal 
especially jejuno-ileal origin  [75] . Other markers such as 
E-cadherin, p53, p27, VEGF and others have not been es-
tablished as yet for routine diagnostics, although they 
may play a role in the future  [76–78] .
 A familial or genetic predisposition to Si-NEN has not 
been established; however, recent reports have shown 
some familial associations which strongly suggest that a 
genetic predisposition may exist in rare instances  [79–
81] . Other changes such as allelic loss of chromosome 18q 
have been reported to indicate adverse prognosis, but 
currently they have no role outside of research studies 
 [82, 83] . There is no indication to perform germline or 
somatic DNA testing and genetic counseling in the ab-
sence of other tumors or a family history.
 Minimal Consensus Statement on Pathology  
 Histopathology 
 Histology is always necessary to establish the diagnosis of a 
NEN. Cytology may be helpful, particularly in a metastatic set-
ting. The minimal ancillary tests to support a histological diagno-
sis include immunohistochemistry for CgA, synaptophysin and, 
optionally, serotonin. The mitotic count in 10 HPF (2 mm 2 ) eval-
uated in areas of highest mitotic density, the Ki-67 index (MIB1 
antibody; percentage of 2,000 cells in areas of highest nuclear la-
beling) and TNM staging according to the UICC classification 
and ENETS guidelines should be reported. Immunohistochemis-
try for cdx-2, p53 and SSR-2 is optional. The histopathology re-
port should allow for a correct classification according to the cur-
rent WHO criteria. In the future, it should also provide informa-
tion for a correct TNM classification and grading ( table 1 a–c). 
 Figure 1 summarizes the diagnostic algorithm of Si-NEN.
Table 1. TNM classification, staging and grading of Si-NENs 
according to the ENETS guidelines and UICC classification [3, 20, 
72]
a TNM classification of Si-NENs
T – Primary tumor
x Primary tumor cannot be assessed
0 No evidence of primary tumor
1 Tumor invades mucosa or submucosa and size ≤1 cm
2 Tumor invades muscularis propria or size >1 cm
3 Tumor invades subserosa
4 Tumor invades peritoneum/other organs
for any T add (m) for multiple tumors
N – Regional lymph node metastasis
x Regional lymph nodes cannot be assessed
0 No regional lymph node metastasis
1 Regional lymph node metastasis
M – Distant metastasis
x Distant metastasis cannot be assessed
0 No distant metastasis
1 Distant metastasis
b Staging of Si-NENs
Stage TNM Disease
0 T is N0 M0 localized
(Stage 0: ENETS only)
I T1 N0 M0
II a T2 N0 M0
b T3 N0 M0
III a T4 N0 M0
b any T N1 M0 regional
IV any T any N M1 distant
c Grading of Si-NENs
Grade Ki-67 index (%) Mitotic index 
(mitoses/10 HPF)
G1 ≤2 <2
G2 3 – 20 2 – 20
G3 >20 >20
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 Curative Surgery 
 Figure 2 summarizes a proposed therapeutic algo-
rithm for Si-NENs.
 Resection of Localized and Regional Disease
(Stage I–III) 
 All patients with Si-NENs should be considered poten-
tial candidates for curative surgery of the primary tumor 
and regional lymph-node metastasis  [76, 78–81, 83] . Pa-
tients should be evaluated in a multidisciplinary setting 
including an experienced visceral surgeon  [7, 25, 30, 31, 
84–91] . Curative resection of the primary tumor and dis-
section of the locoregional lymph node metastasis along 
the superior mesenteric root and around the mesentery, 
aiming to preserve the vascular supply  [92] , improve the 
outcome in these patients resulting in excellent 5- and 10-
year survival rates of 100% in stage I and II patients and 
>95% and >80%, respectively, in stage III Si-NEN patients 
 [21] . The review of a large number of surgical patients 
demonstrated that regional mesenteric lymphadenecto-
my in conjunction with the resection of the primary tu-
mor is associated with improved survival of Si-NEN pa-
tients  [93] 
 Any surgical procedure should follow the principles of 
oncological surgery in the small intestinal tract  [84–91] , 
but sometimes a concomitant right-sided hemicolectomy 
may be required if the tumor is located in the terminal 
ileum. Age, disease stage and complete resection were 
identified as independent prognostic factors for survival 
in Si-NEN patients. Localized and regionally restricted 
(Stage I–III) Si-NENs have an excellent prognosis after 
radical surgical treatment. The importance of achieving 
R0 resection is therefore emphasized  [94, 95] . To limit the 
extent of small intestinal resection, lymphatic mapping 
has been suggested to be helpful, but it is not a standard-
ized procedure and therefore not generally recommend-
ed  [96, 97] . 
 tnatsiD lanoigeR dezilacoL esaesiD
 VI III II/I egatS
TNM T1–3N0M0 
 
T4N0M0 
T1–4N1M0 
 
 TxNxM1  
Surgical treatment Radical resection Radical resection with curative intent Palliative resection No resection 
 
Local radical open (or in selected pts) 
laparoscopic resection* of 
?  primary tumor(s)** 
?  lymph nodes (dissection along the 
superior mesenteric root) 
Local radical open 
resection of 
?  primary 
tumor(s) 
?  lymph nodes 
(dissection 
along the 
superior 
mesenteric 
root)  
 
in combination 
with: 
?  mets (liver) 
Local radical open (in 
selected pts) 
laparoscopic resection 
of 
?  primary 
tumor(s) 
?  lymph nodes 
(dissection 
along the 
superior 
mesenteric 
root) 
Due to: 
?  local 
inoperability 
?  comorbidity 
 romut morf eerF romut morf eerF miA
?  To avoid local 
complications 
(obstruction, 
bleeding etc.) 
?  To possibly 
improve 
prognosis* 
 
 Fig. 2. Therapeutic algorithm for Si-NENs. Pts = Patients; mets = metastasis.  * For details, see the text.  * * Caution: multiple primaries. 
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 A minimally invasive approach can be considered, 
provided that oncological surgical standards can be 
achieved; however, patients with large mesenteric infil-
tration and multiple tumors are probably not optimal 
candidates for laparoscopic resection. The level of evi-
dence for the role of laparoscopic surgery for Si-NEN is 
low. There is a lack of randomized trials. Only few single-
center studies describe small numbers of patients after 
laparoscopic resection of primary Si-NENs  [98] . Laparo-
scopic techniques are feasible and safe and are to be fa-
vored due to the general advantages of a laparoscopic sur-
gical approach; however, the potential benefits of mini-
mally invasive surgery have to be weighed against the risk 
of incomplete (i.e. noncurative) tumor resection (espe-
cially in the event of multiple small Si-NENs). 
 Postoperative malabsorption and/or bile-salt-induced 
diarrhea due to the resection of more or less extensive 
parts of the distal small intestine, and particularly the ter-
minal ileum, may be observed and require either medical 
(e.g. cholestyramine) or nutritional therapy. However, 
postoperative mortality should be <2% and significant 
morbidity <20%  [28, 87] .
 Concomitant Cholecystectomy 
 Since cholelithiasis appears to be increased in NEN pa-
tients, particularly in those on SSA therapy, cholecystec-
tomy has been recommended even for nonsymptomatic 
patients in the past  [99] . However, prospective proof of 
this concept has never been produced, and there is an on-
going debate as to whether routine cholecystectomy is re-
quired or not  [100, 101] because the increased incidence 
of cholelithiasis does not consistently lead to cholecysti-
tis. It may therefore be individually decided by the sur-
geon, depending on technical and clinical aspects (e.g.
the presence of cholelithiasis, previous episodes of chole-
cystitis or cholangitis, presumed cholecystitis-associated 
right upper abdominal pain, planned transarterial che-
mo-/embolization or selective internal radiotherapy and 
the intraoperative risk of cholecystectomy in an emergen-
cy situation). However, a prophylactic cholecystectomy 
should be performed at laparotomy if patients are planned 
to undergo treatment with SSAs  [100] .
 Minimal Consensus Statement on Curative Surgery 
 Curative surgery is always recommended whenever feasible. 
Surgery of the primary should be performed as segmental resec-
tion with wide lymphadenectomy. In case of lymph node in-
volvement around the superior mesenteric artery, high lymph 
node dissection is recommended. In cases with severe desmo-
plastic reaction around the artery, radical tumor resection may 
not be possible. 
 Cholecystectomy may be performed during the initial session 
as prophylaxis against the development of gallstones (frequent in 
patients that will require SSA treatment), although the benefit of 
cholecystectomy has never been prospectively proven. In emer-
gency situations, cholecystectomy may therefore not be enforced.
 Tumor multicentricity, which may occur in 20% of all cases, 
demonstrated by SRS, cross-sectional imaging, intraoperative 
palpation and/or endoscopy, does not change the indication for 
surgery. A minimally invasive (laparoscopic) approach may be 
considered, provided that oncological surgical standards can re-
alistically be achieved; patients with large mesenteric infiltration 
and multiple tumors are not candidates for extended laparoscop-
ic procedures. 
 The outcome of surgery may be worse in cases with distant 
metastases other than in the liver, as well as in cases with the so-
called frozen mesenteric root and peritoneal carcinomatosis. 
Careful pre- and perioperative symptomatic control of any car-
cinoid syndrome can be achieved by medical treatment (s.c. or 
i.v. SSAs).
 After curative surgery, there is no indication for specific med-
ical treatment, and there is no proven role for neoadjuvant or 
adjuvant medical treatment in Si-NEN patients.
 Palliative Surgery in Distant Disease (Stage IV)  
 Palliative (Prophylactic) Resection of the Primary 
Tumor in Metastatic Disease 
 In cases with distant metastases, the decision of 
whether to resect the primary tumor or not is influenced 
by three considerations: (1) if a curative approach in-
cluding the curative resection of the distant metastases 
(mostly liver metastases)  [102] can still be reasonably 
achieved, then a primary tumor resection should be
performed following oncological standards as outlined 
above  [103] . (2) In symptomatic patients with symp-
toms due to small intestinal obstruction, (impeding) oc-
clusion or tumor bleeding, the palliative resection of the 
primary tumor is obviously mandatory to prevent clini-
cal deterioration or death. To avoid local vessel occlu-
sion with ischemic bowel complications by intra-ab-
dominal fibrosis, mesenteric lymph node metastases 
should also be removed as completely as possible. (3) If 
a curative approach seems no longer achievable, prima-
ry tumor resection may still improve the overall out-
come and can therefore be considered  [28, 104] , al-
though this has not been shown to be reproducible in all 
series  [25] . However, these data are all influenced by 
their retrospective nature and a potential ‘surgical’ bias 
favoring resectable and thus less morbid patients. Thus, 
in the third setting, comorbidities should be carefully 
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considered, probably best in an interdisciplinary setting 
to avoid unnecessary risks to the patient.
 As shown recently, available data from six comparable 
clinical observational studies suggest a possible benefit of 
local resection of the primary Si-NEN and the regional 
metastasis in patients with unresectable liver metastases, 
but the studies included in the systematic review of the 
literature have several limitations, and the results should 
therefore be considered with caution  [105] .
 The aspects of debulking surgery were discussed in the 
previous guidelines  [102, 106] .
 Minimal Consensus Statement on Palliative Resection 
in Stage IV 
 Palliative resection for patients with endocrine tumors of the 
jejuno-ileum has the objective to make liver metastases the only 
persisting problem or to improve prognosis. 
 A resection of the small intestinal primary tumor should be 
attempted because the overall outcome is better in patients after 
primary tumor resection, although a direct causal relationship 
has not been proven to date; a multidisciplinary discussion is rec-
ommended for such a decision. Resection should also be consid-
ered in symptomatic patients and in patients in whom imaging 
(bowel dilatation, mesenteric fibrosis) suggests that obstruction 
will probably occur. 
 Patients suitable for palliative debulking procedures are those 
presumed to benefit from tumor reduction performed in accor-
dance with given guidelines. Palliative surgery should mainly be 
done for symptomatic reasons or to facilitate other therapeutic 
modalities, i.e. medical and radionuclide treatment. The type of 
surgery should be individualized, no general approach can be 
recommended. If liver metastasis requires a minor resection, this 
can be done at the same procedure as the primary, otherwise it 
should be done at a second operation. 
 In the palliative setting, medical therapy is frequently re-
quired pre-, peri- and postoperatively. For further recommenda-
tions, please refer to the paper on metastasis  [102] .
 CHD (Hedinger Syndrome) 
 CHD can be detected in 25–50% of all patients with the 
carcinoid syndrome  [28, 30, 107–114] . Recently, the cur-
rent knowledge of its pathophysiology and treatment
has been summarized by Grozinsky-Glasberg et al.  [114] . 
CHD indicates a poor prognosis and is associated with 
clinical signs of right-sided heart failure, echocardio-
graphic signs of right ventricular dilatation or tricuspid 
valve regurgitation depending on the duration of CHD. 
Prognosis has improved over the last 20 years from a 
5-year survival from <30% in the 1980s to now approxi-
mately 55%. The most important reason for this improve-
ment is successful cardiac surgery with valve replacement 
 [108, 109, 111, 115] . CHD is characterized by plaque-like 
fibrous endocardial thickening that principally involves 
the right side of the heart, causing retraction and fixation 
of the leaflets of the tricuspid and pulmonary valves as 
well as diminished right ventricular function  [115–118] . 
These changes are thought to be elicited by excess sero-
tonin release (patients usually have very high levels of se-
rotonin and/or urinary 5-HIAA levels) and co-secretion 
of other fibrogenic factors such as tachykinins, connec-
tive tissue growth factor, transforming growth factor-β 
and/or substance P  [113, 115, 116] .
 Transthoracic echocardiography is the most impor-
tant diagnostic modality  [107, 110, 111] , although cardiac 
MRI  [119] and other newer techniques such as tissue 
Doppler imaging  [120] may play a role in the future. Na-
triuretic peptides such as brain natriuretic peptide and its 
precursors have also been shown to be quite sensitive in-
dicators of early CHD and may be monitored regularly 
for early detection of CHD when available  [120] . Screen-
ing for CHD should be performed on a regular basis, par-
ticularly prior to planned surgical procedures. If it devel-
ops, heart failure rather than metastatic disease may be 
the cause of death. Medical therapy for heart failure 
should be introduced when necessary. SSAs are manda-
tory and have shown improvement in cardiac reserve,
although they may not prevent CHD progression, and 
cardiac surgery with valve replacement (bioprosthesis) 
should be considered for patients in whom control of
hormonal symptoms and tumor growth has been 
achieved. Cardiac surgery should be performed before 
major liver surgery or liver embolization, while on the 
other hand early liver metastasis resection may slow the 
progression of CHD particularly in its earlier stages.
 More recently, the coexistence of a patent foramen 
ovale (PFO) has been described together with CHD  [121–
123] , and it may increase the chance of left-sided heart 
lesions; its closure has also improved functional outcome 
in CHD patients. A PFO should therefore be ruled out in 
clinically progressing CHD and prior to cardiac surgery. 
 Minimal Consensus Statement on CHD 
 For patients with the carcinoid syndrome and CHD, trans-
thoracic echocardiography should be performed annually; car-
diac MRI may be helpful but its usefulness has not been proven 
as yet. SSAs are usually indicated in these patients presenting 
with often advanced carcinoid syndrome. For the timing of car-
diac surgery with replacement of the tricuspid (and pulmonary) 
valves, brain natriuretic peptide measurements may be helpful, 
since they reflect the load on the right side of the heart. At car-
diac imaging, a PFO should be ruled out; if present, its closure 
should be considered although only sparse data exist for this ap-
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proach. Decisions towards cardiologic intervention or cardiac 
surgery should be made on an individual basis in collaboration 
with an experienced cardiologist and cardiac surgeon.
 Follow-up 
 A precise follow-up strategy is described in the ENETS 
standards of care  [124] . Briefly, for patients having un-
dergone surgery with a curative intent, the schedule for 
follow-up should be every 6–12 months, with the excep-
tion of G3 tumors, which should be followed every 3 
months. Patients treated without curative intent should 
be followed initially at 3–6 months’ intervals for G1/G2 
neuroendocrine tumors, and this can be lengthened in 
very slowly progressive tumors. In very rare G3 neuroen-
docrine carcinomas, the intervals should not exceed 3 
months. Minimal examination includes the measure-
ment of CgA and 5-HIAA and a triphasic CT. SRI (SRS 
or PET/CT) should be performed in suspected recurrenc-
es before any therapeutic decisions are made, or even af-
ter curative resection with unknown NEN prior to sur-
gery to rule out distant metastases. The follow-up should 
be life-long, considering that after 25 years only approxi-
mately 20% of all patients are free of disease  [30, 125] .
 Minimal Consensus Statement on Follow-up 
 For guidelines regarding follow-up strategies, we recommend 
to follow the ENETS standards of care.
 Please also refer to the consensus guideline updates for 
other gastroenteropancreatic neuroendocrine tumors 
[ 126–131 , this issue].
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